UNSPSC 51162003: Aminophylline/ammonium chloride/diphenhydramine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE109. This VA Drug Class (RE109) classifies this compound as belonging to the group ANTIASTHMA, OTHER.

UNSPSC 51162003 Aminophylline/ammonium chloride/diphenhydramine, a Commodity code, captures pharmaceutical procurement that state and local governments are actually buying as part of broader health service delivery and drug management programs rather than narrow single-ingredient products. Recent state and local solicitations tagged under this code span naloxone (opioid reversal) kits, on-site pharmacy services for government employee health plans, direct-to-manufacturer prescription programs, and generic multi-source pharmaceutical contracts. Issuing bodies include county health departments (Seminole County, Florida; Hall County, Georgia), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing vehicles (Minnesota Multistate Cooperative Purchasing Alliance, MMCAP). The actual work involves procurement of finished pharmaceutical products for inventory stocking, emergency response, and employee/retiree health plan coverage, bundled with dispensing, logistics, compliance, and pricing management rather than purchase of bulk active ingredients.

Activity spans Florida, Georgia, Texas, and a multistate cooperative including Minnesota and Oregon. Seminole County, Florida issued an IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries due July 26, 2023, requiring E-Verify compliance and two-year terms with optional renewal. Hall County, Georgia posted an RFQ/P for on-site pharmacy services at its Family Health Center serving approximately 3,005 eligible individuals across three insurance plans, with proposals due June 4, 2026, using an 80/20 technical-to-cost scoring structure and a one-year term beginning January 1, 2027 with four optional renewal years. Texas HHS Commission issued an RFI on March 27, 2026 (due April 3, 2026) to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program aimed at improving fulfillment efficiency outside traditional pharmacy benefit manager channels. MMCAP, administered by Minnesota Department of Administration, posted an RFP due March 26, 2026 for generic multi-source pharmaceuticals and OTC products to be distributed through three authorized wholesalers, with awards effective July 1, 2026 and pricing weighted at 75 percent of the evaluation score.